This study is the first to evaluate aspirin as adjuvant therapy in established cancers, and has been tipped as one of the most important gastrointestinal cancer studies globally. In 2012, the National Cancer Institute of U.S listed aspirin’s role in cancer as one of the most provocative questions in cancer research. The AGITG has also recently ranked “Aspirin in Colorectal Cancer” – as the top research priority in gastrointestinal cancer, and has therefore committed to recruiting for ASCOLT. The trial is led by an international collaboration from Singapore, UK and Australia. To find out more click here